|Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin|
RD Morin, NA Johnson, TM Severson, AJ Mungall, J An, R Goya, JE Paul, ...
Nature genetics 42 (2), 181, 2010
|Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma|
RD Morin, M Mendez-Lago, AJ Mungall, R Goya, KL Mungall, RD Corbett, ...
Nature 476 (7360), 298, 2011
|Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma|
RE Davis, VN Ngo, G Lenz, P Tolar, RM Young, PB Romesser, ...
Nature 463 (7277), 88, 2010
|Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone|
NA Johnson, GW Slack, KJ Savage, JM Connors, S Ben-Neriah, S Rogic, ...
Journal of clinical oncology 30 (28), 3452, 2012
|MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy|
KJ Savage, NA Johnson, S Ben-Neriah, JM Connors, LH Sehn, P Farinha, ...
Blood 114 (17), 3533-3537, 2009
|Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival|
NA Johnson, KJ Savage, O Ludkovski, S Ben-Neriah, R Woods, C Steidl, ...
Blood 114 (11), 2273-2279, 2009
|MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers|
C Steidl, SP Shah, BW Woolcock, L Rui, M Kawahara, P Farinha, ...
Nature 471 (7338), 377, 2011
|Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma|
R Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ...
Journal of Clinical Oncology 35 (19), 2125, 2017
|Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing|
RD Morin, K Mungall, E Pleasance, AJ Mungall, R Goya, RD Huff, ...
Blood 122 (7), 1256-1265, 2013
|EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis|
I Velichutina, R Shaknovich, H Geng, NA Johnson, RD Gascoyne, ...
Blood 116 (24), 5247-5255, 2010
|Prognostic factors in follicular lymphoma|
T Relander, NA Johnson, P Farinha, JM Connors, LH Sehn, ...
J Clin Oncol 28 (17), 2902-2913, 2010
|BCL2 predicts survival in germinal center B-cell–like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab|
J Iqbal, PN Meyer, LM Smith, NA Johnson, JM Vose, TC Greiner, ...
Clinical cancer research 17 (24), 7785-7795, 2011
|Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP|
LM Rimsza, ML LeBlanc, JM Unger, TP Miller, TM Grogan, DO Persky, ...
Blood 112 (8), 3425-3433, 2008
|Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival|
NA Johnson, M Boyle, A Bashashati, S Leach, A Brooks-Wilson, LH Sehn, ...
Blood 113 (16), 3773-3780, 2009
|Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis|
KJJ Cheung, NA Johnson, JG Affleck, T Severson, C Steidl, S Ben-Neriah, ...
Cancer research 70 (22), 9166-9174, 2010
|Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances|
KJJ Cheung, SP Shah, C Steidl, N Johnson, T Relander, A Telenius, B Lai, ...
Blood 113 (1), 137-148, 2009
|DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma|
R Shaknovich, H Geng, NA Johnson, L Tsikitas, L Cerchietti, JM Greally, ...
Blood 116 (20), e81, 2010
|The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival|
D O'Shea, C O'Riain, C Taylor, R Waters, E Carlotti, F MacDougall, ...
Blood 112 (8), 3126-3129, 2008
|Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP|
R Malumbres, J Chen, R Tibshirani, NA Johnson, LH Sehn, Y Natkunam, ...
Blood 111 (12), 5509-5514, 2008
|Systemic cancer therapy: achievements and challenges that lie ahead|
MO Palumbo, P Kavan, W Miller, L Panasci, S Assouline, N Johnson, ...
Frontiers in pharmacology 4, 57, 2013